Melior

Melior Is Recognized as CRO of the Year by Life Sciences Review

Retrieved on: 
Tuesday, March 19, 2024
Biotechnology, Pharmaceutical, Health, Other Health, Disease, ChromeOS, Melior, Fine chemical

Melior Discovery, Inc. (Melior) announced today that it has been selected as the CRO of the Year by Life Sciences Review magazine.

Key Points: 
  • Melior Discovery, Inc. (Melior) announced today that it has been selected as the CRO of the Year by Life Sciences Review magazine.
  • The year-end edition of the magazine is dedicated to coverage of 10 preeminent CROs, among which Melior was selected as CRO of the Year.
  • These platform offerings are in addition to Melior’s broad array of animal models of human disease.
  • “I am tremendously honored by this acknowledgment from the editors of Life Sciences Review,” said Andrew Reaume, Melior’s President and CEO.

Melior Is Selected as a Top 20 CRO by Pharma Tech Outlook

Retrieved on: 
Thursday, June 22, 2023
Biotechnology, Pharmaceutical, Health, Melior, Fine chemical

Melior Discovery, Inc. (Melior) announced today that it has been selected as a top-20 CRO in the most recent edition of Pharma Tech Outlook magazine.

Key Points: 
  • Melior Discovery, Inc. (Melior) announced today that it has been selected as a top-20 CRO in the most recent edition of Pharma Tech Outlook magazine.
  • This cover story article recognized Melior’s approach towards providing bespoke solutions in the preclinical in vivo pharmacology space and its pioneering achievements in phenotypic screening vis-à-vis its theraTRACE® platform.
  • “I am very proud of the acknowledgment provided by the Pharma Tech editors on the strides that we have been making in strengthening Melior’s offering” said Andrew Reaume, Melior’s president and CEO.
  • “We have especially been doubling down on the work culture here, as evidenced by our recognition as a Great Place To Work® business, and the quality that follows through from that to our clients.”
    The online edition of this article can be read at: https://www.pharmatechoutlook.com/magazines/June2023/CRO/

Melior Announces Substantial Additions to Its Management and Scientific Team

Retrieved on: 
Tuesday, April 12, 2022
Pharmaceutical, Health, Oncology, Foundation for the National Institutes of Health, CEO, Pain, Lists of diseases, LLC, MBA, Doctor of Philosophy, Pfizer, Inflammation, Hospital, GlaxoSmithKline, Research and development, Environment, Research associate, Hospital for Sick Children (Toronto), National Institute, PDX, Toronto, Neurodegeneration, Melior Discovery, Knowledge, Management, Pharmaceutical industry, Oncology, Pharmacology, Melior, Research

Melior Discovery, Inc. (Melior) announced today significant additions to its management organization.

Key Points: 
  • Melior Discovery, Inc. (Melior) announced today significant additions to its management organization.
  • Joining the Melior organization will be Dr. Ken Kilgore (PhD, MBA) as Vice President of Pharmacology.
  • In addition, Melior veteran, Dr. Vivian Cong, will rise to the role of Vice President of Research and Development.
  • Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA. For more information, visit www.meliordiscovery.com and www.meliorpharma.com .

Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders

Retrieved on: 
Monday, November 22, 2021
Patient, Movement, Canadian Intellectual Property Office, PD, Investigational New Drug, Company, Rouge, ATRX, Melior Discovery, IND, Melior, Central nervous system, Psychiatry, Sirna, GLOBE, LLC, Patent, RNA, NASH, FAP, Therapy, Type 1 diabetes, Drug development, Fatty liver disease, Pharmaceutical industry

Melior has received a Notice of Allowance from the Canadian Intellectual Property Office for the patent, titled, Methods of Treating Dyskinesia and Related Disorders.

Key Points: 
  • Melior has received a Notice of Allowance from the Canadian Intellectual Property Office for the patent, titled, Methods of Treating Dyskinesia and Related Disorders.
  • Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various psychiatric and central nervous system indications.
  • Adhera is developing MLR-1023 (tolimidone) as a new drug for Type I diabetes with a focus on C-peptide positive patients.
  • Adhera also has exclusive rights to develop MLR-1023 for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation diseases and conditions.

Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications

Retrieved on: 
Wednesday, October 20, 2021
Fatty liver disease, Liver, Immune system, Risk, Degenerative disease, Yolk sac, Contributor License Agreement, Mortal Kombat, Death, FAP, License, Private Securities Litigation Reform Act, COVID-19, NASH, PD, Melior Discovery, U.S. Securities and Exchange Commission, Pulmonary edema, Sirna, Growth hacking, Diabetes, Security (finance), Drug development, RNA, Coronavirus, Disease, Central nervous system, Severe acute respiratory syndrome, Melior, Pharmacology, Research, Sepsis, Infection, Vaccine, Therapy, Safety, Psychiatry, Patient, LLC, Forward-looking statement, SARS, Type 1 diabetes, Cytokine, Lists of diseases, Company, Movement, Pharmaceutical industry

NASH is also a metabolic disease where, much like diabetes, lyn kinase expression could be an ideal pathway to developing next-generation treatments.

Key Points: 
  • NASH is also a metabolic disease where, much like diabetes, lyn kinase expression could be an ideal pathway to developing next-generation treatments.
  • Regarding pulmonary edema, MLR-1023 is clearly differentiated from commonly used therapeutics today, including anti-inflammatory drugs and vaccines.
  • Adhera also has exclusive rights to develop MLR-1023 for Non-Alcoholic Steatohepatitis (NASH) and pulmonary inflammation diseases and conditions.
  • Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA. For more information, visit www.meliordiscovery.com and www.Meliorpharmaceuticals.com .

Announcement of Post-RTO Ownership Position in Ranchero Gold (formerly Melior Resources)

Retrieved on: 
Tuesday, October 12, 2021
Company, Mining, Loan, Castle Street, RTO, Concurrency, Consolidation, Indian stock exchange, Debt settlement, GLOBE, TSX Venture Exchange, Loan agreement, SEDAR, Investment, Melior, Conversion, Cryptocurrency, Security (finance)

TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Pala Investments Limited (“Pala”), a multi-strategy investment company focused on the mining and metal value chain, provided an update today on its ownership position in Ranchero Gold Corp. (formerly Melior Resources Inc.) (the “Company”) following the completion of the Company’s reverse-takeover transaction with Ranchero BC Holding Corp. (the “RTO”) (formerly Ranchero Gold Corp.) (“Ranchero”), which closed on October 8, 2021. Prior to the completion of the RTO, Melior Resources Inc. changed its name to “Ranchero Gold Corp.” and consolidated its common shares (the “Consolidation”) on the basis of 32.6764 pre-Consolidation common shares (the “Melior Shares”) for one post-Consolidation common share (the “Common Shares”). Additional details about the RTO and related matters are available in the Company’s press release dated October 8, 2021 and its filing statement dated September 30, 2021, which are both available under the SEDAR profile of the Company at www.sedar.com.

Key Points: 
  • Prior to the completion of the RTO, Melior Resources Inc. changed its name to Ranchero Gold Corp. and consolidated its common shares (the Consolidation) on the basis of 32.6764 pre-Consolidation common shares (the Melior Shares) for one post-Consolidation common share (the Common Shares).
  • Pala was issued 51,378,211 Melior Shares (representing 1,572,334 post-Consolidation Common Shares) in respect of the Conversion.
  • Immediately prior to the RTO and the other transactions referred to above, Pala held 14,132,543 Melior Shares, representing approximately 47% of the outstanding Melior Shares (based on there being 29,901,770 Melior Shares issued and outstanding).
  • As a result of the Conversion, the Debt Settlement and the Subscription, Pala acquired ownership and control over 7,177,032 Common Shares.

Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias

Retrieved on: 
Monday, October 4, 2021
Melior, Patent, End-user license agreement, Therapy, European Patent Convention, RNA, Risk, Security (finance), Investigational New Drug, License, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Melior Discovery, Patient, FAP, Central nervous system, Writing, GLOBE, Company, Sirna, LLC, Eating, PD, Embarrassment, ATRX, IND, Research, Psychiatry, Drug development, Safety, Forward-looking statement, Intellectual property, Movement, Rouge, Type 1 diabetes, European Patent Office, Pharmaceutical industry

Melior has received notice from the European Patent Office that the patent, titled, Methods of Treating Dyskinesia and Related Disorders, passed the required period without any opposition being filed, triggering the issuance of the patent.

Key Points: 
  • Melior has received notice from the European Patent Office that the patent, titled, Methods of Treating Dyskinesia and Related Disorders, passed the required period without any opposition being filed, triggering the issuance of the patent.
  • Given that our development plans for MLR-1019 begin in Eastern Europe, the new patent is particularly timely as part of a robust patent portfolio protecting the intellectual property, commented Andrew Kucharchuk, Chief Executive Officer at Adhera Therapeutics.
  • Dyskinesias have a negative impact both functionally and socially on most Parkinsons patients, causing embarrassment while inhibiting their ability for daily tasks, including writing, dressing, and eating.
  • A more complete description of these risk factors is included in Adhera Therapeutics filings with the Securities and Exchange Commission.

Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson’s Disease and Type 1 Diabetes Drugs

Retrieved on: 
Monday, September 13, 2021
Risk, Type 1, U.S. Securities and Exchange Commission, Movement, Therapy, Melior Discovery, Security (finance), Central nervous system, CEO, Sirna, University, Drug development, Forward-looking statement, PD, Doctor of Philosophy, Patient, NPV, Company, Private Securities Litigation Reform Act, Drug repositioning, LLC, Type 2, Type 1 diabetes, Genetics, FAP, IND, ATRX, Entrepreneurship, Safety, NASDAQ, Rouge, Investigational New Drug, License, RNA, Type 2 diabetes, MBA, Psychiatry, GLOBE, OTC, Melior, Contributor License Agreement, Research, Wendell Pritchett, Wharton School of the University of Pennsylvania, Pharmaceutical industry

On July 29, 2021 and August 24, 2021 , respectively, the Company announced executing exclusive license agreements for MLR-1019 for Parkinsons disease (PD) and MLR-1023 for Type 1 diabetes.

Key Points: 
  • On July 29, 2021 and August 24, 2021 , respectively, the Company announced executing exclusive license agreements for MLR-1019 for Parkinsons disease (PD) and MLR-1023 for Type 1 diabetes.
  • Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways.
  • Adhera is developing MLR-1023 (tolimidone) as a new drug for Type I diabetes with a focus on C-peptide positive patients.
  • A more complete description of these risk factors is included in Adhera Therapeutics filings with the Securities and Exchange Commission.

Adhera Therapeutics Signs Exclusive License Agreement with Melior Pharmaceuticals I for New Type 1 Diabetes Drug Candidate

Retrieved on: 
Tuesday, August 24, 2021
Company, Type 1, Pharmacology, LLC, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Sirna, C-peptide, GLOBE, Immune system, Security (finance), Research, ATRX, RNA, Baton Rouge, Louisiana, Prevalence, Therapy, Pancreas, JDRF, Forward-looking statement, Risk, Safety, Melior, Patient, End-user license agreement, Insulin, FAP, License, Pharmaceutical industry

Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways.

Key Points: 
  • Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways.
  • Melior Discovery and its companies, Melior Pharmaceuticals I, Inc. and Melior Pharmaceuticals II, LLC, are leaders in pharmaceutical drug repositioning using the unique theraTRACE platform comprised of multiplexed in vivo disease models.
  • Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA. For more information, visit www.meliordiscovery.com and www.meliorpharma.com .
  • A more complete description of these risk factors is included in Adhera Therapeutics filings with the Securities and Exchange Commission.

Adhera Signs Definitive License Agreement with Melior Pharmaceuticals II for New Parkinson’s Disease Drug Candidate

Retrieved on: 
Thursday, July 29, 2021
Melior Discovery, Health care, Melior, Health sciences, Health, Pharmaceutical industry in China, Drug repositioning

To the best of either companies knowledge, MLR-1019 will be the only drug candidate in development that addresses both movement (e.g., facial masking, dyskinesia, etc.)

Key Points: 
  • To the best of either companies knowledge, MLR-1019 will be the only drug candidate in development that addresses both movement (e.g., facial masking, dyskinesia, etc.)
  • Melior Discovery and its companies, Melior Pharmaceuticals I, Inc. and Melior Pharmaceuticals II, LLC, are leaders in pharmaceutical drug repositioning using the unique theraTRACE platform comprised of multiplexed in vivo disease models.
  • Melior Discovery and Melior Pharmaceuticals are privately held and located in Exton, PA. For more information, visit www.meliordiscovery.com and www.meliorpharma.com .
  • A more complete description of these risk factors is included in Adhera Therapeutics filings with the Securities and Exchange Commission.